Members Login
Medical News Feed
EPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Drug details for : XERISTAR
| Drug class description : | Other antidepressants |
| Generic Name : | Duloxetine |
| Drug description : | Hard gastro-resistant capsule. The XERISTAR 30 mg capsule has an opaque white body, imprinted with ‘30 mg’ and an opaque blue cap, imprinted with ‘9543’. |
| Presentation : | 30 mg hard gastro-resistant capsules The active ingredient in XERISTAR is duloxetine. Each capsule contains 30 mg of duloxetine as duloxetine hydrochloride |
| Indications : | Treatment of major depressive episodes. Treatment of diabetic peripheral neuropathic pain in adults. |
| Adult Dosage : | For oral use. Adults Major Depressive Episodes: The starting and recommended maintenance dose is 60 mg once daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations. Therapeutic response is usually seen after 2-4 weeks of treatment. After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse. Diabetic Peripheral Neuropathic Pain: The starting and recommended maintenance dose is 60 mg daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. The plasma concentration of duloxetine displays large inter-individual variability. Hence, some patients that respond insufficiently to 60 mg may benefit from a higher dose. The medicinal product response should be evaluated after 2 months’ of treatment. Additional response after this time is unlikely. The therapeutic benefit should regularly (at least every three months) be reassessed. Diabetic Peripheral Neuropathic Pain: No dosage adjustment is recommended for elderly patients solely on the basis of age. However, caution should be exercised when treating the elderly. Hepatic impairment XERISTAR should not be used in patients with liver disease resulting in hepatic impairment (See Contraindications). Renal insufficiency No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min). See Contraindications for severe renal impairment. Discontinuation of treatment When discontinuing XERISTAR after more than 1 week of therapy, it is generally recommended that the dose be tapered over no less than 2 weeks before discontinuation in an effort to decrease the risk of discontinuation symptoms. As a general recommendation, the dose should be reduced by half or administered on alternate days during this period. The precise regimen followed should however take into account the individual circumstances of the patient, such as duration of treatment, dose at discontinuation etc. |
| Child Dosage : | Children and adolescents The safety and efficacy of duloxetine in these age groups have not been studied. Therefore, administration of XERISTAR to children and adolescents is not recommended (See Special Precautions). |
| Elderly Dosage : | Major Depressive Episodes: No dosage adjustment is recommended for elderly patients solely on the basis of age. However, as with any medicine, caution should be exercised when treating the elderly, especially with XERISTAR 120 mg per day for which data are limited (See Special Precautions). |
| Contra Indications : | Hypersensitivity to the active substance or to any of the excipients. Concomitant use of XERISTAR with nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs) is contraindicated (See Interactions). Liver disease resulting in hepatic impairment. XERISTAR should not be used in combination with fluvoxamine, ciprofloxacin or enoxacine (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (See Interactions). Severe renal impairment (creatinine clearance <30 ml/min). |
| Special Precautions : | Mania and seizures XERISTAR should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures. Mydriasis Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing XERISTAR to patients with increased intraocular pressure, or those at risk of acute narrow-angle glaucoma. Blood pressure In patients with known hypertension and/or other cardiac disease, blood pressure monitoring is recommended as appropriate. Renal impairment Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance <30 ml/min). For patients with severe renal impairment, see Contraindications. See Adult Dosage for information on patients with mild or moderate renal dysfunction. Use with antidepressants Caution should be exercised when using XERISTAR in combination with antidepressants. In particular the combination with selective reversible MAOIs is not recommended. St John’s wort Undesirable effects may be more common during concomitant use of XERISTAR and herbal preparations containing St John’s wort (Hypericum perforatum). Suicide Major Depressive Episodes Depression is associated with an increased risk of suicidal thoughts, self harm and suicide. This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stages of recovery. Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Close supervision of high-risk patients should accompany drug therapy (See Adverse Reactions). Patients, (and caregivers of patients) should be alerted about the need to monitor for the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. Diabetic Peripheral Neuropathic Pain As with other medicinal products with similar pharmacological action (antidepressants), isolated cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Physicians should encourage patients to report any distressing thoughts or feelings at any time. Use in children and adolescents under 18 years of age No clinical trials have been conducted with duloxetine in paediatric populations. XERISTAR should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempts and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger), were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking. Sucrose XERISTAR hard gastro-resistant capsules contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine. Haemorrhage There have been reports of cutaneous bleeding abnormalities, such as ecchymoses and purpura with selective serotonin reuptake inhibitors (SSRIs). Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function, and in patients with known bleeding tendencies. Hyponatremia Hyponatremia has been reported rarely, predominantly in the elderly, when administering XERISTAR and other drugs of the same pharmacodynamic class. Discontinuation of treatment Some patients may experience symptoms on discontinuation of XERISTAR, particularly if treatment is stopped abruptly (See Adult Dosage and Adverse Reactions). Elderly Major Depressive Episodes: Data on the use of XERISTAR 120mg in elderly patients with major depressive disorders are limited.. Therefore, caution should be exercised when treating the elderly with the maximum dosage (See Adult Dosage). Medicinal products containing duloxetine Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive episodes as well as stress urinary incontinence). The use of more than one of these products concomitantly should be avoided. |
| Interactions : | CNS medicinal products: the risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section. Consequently, caution is advised when XERISTAR is taken in combination with other centrally acting medicinal products and substances including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines). Monoamine Oxidase Inhibitors (MAOIs): due to the risk of serotonin syndrome, XERISTAR should not be used in combination with nonselective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping XERISTAR before starting an MAOI (See Contraindications). For selective, reversible MAOIs, like moclobemide, the risk of serotonin syndrome is lower. However, the concomitant use of XERISTAR with selective, reversible MAOIs is not recommended (See Special Precautions). Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs (e.g. paroxetine, fluoxetine) concomitantly with serotonergic medicinal products. Caution is advisable if XERISTAR is used concomitantly with serotonergic antidepressants like SSRIs, tricyclics like clomipramine or amitriptyline, St John’s wort (Hypericum perforatum), venlafaxine or triptans, tramadol, pethidine and tryptophan. Effect of duloxetine on other drugs Medicinal products metabolised by CYP1A2: in a clinical study, the pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily). The study was performed in males and it can not be excluded that females having a lower CYP1A2 activity and higher plasma concentrations of duloxetine may experience an interaction with a CYP1A2 substrate. Medicinal products metabolised by CYP2D6: the co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its 5-hydroxyl metabolite and no dosage adjustment is recommended. Caution is advised if XERISTAR is co-administered with medicinal products that are predominantly metabolised by CYP2D6 if they have a narrow therapeutic index. Oral contraceptives and other steroidal agents: results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A. Specific in vivo drug interaction studies have not been performed. Effects of other drugs on duloxetine Antacids and H2 antagonists: co-administration of duloxetine with aluminium- and magnesiumcontaining antacids or duloxetine with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose. Inhibitors of CYP 1A2: because CYP1A2 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine. Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUCo-t 6-fold. Therefore XERISTAR should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (See Contraindications). Inducers of CYP1A2: Population pharmacokinetic studies have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers. Pregnancy There are no data on the use of duloxetine in pregnant women. Studies in animals have shown reproductive toxicity at systemic exposure levels (AUC) of duloxetine lower than the maximum clinical exposure. The potential risk for humans is unknown. As with other serotoninergic drugs, discontinuation symptoms may occur in the neonate after maternal duloxetine use near term. XERISTAR should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Women should be advised to notify their physician if they become pregnant, or intend to become pregnant, during therapy. Breast feeding Duloxetine and/or its metabolites are excreted into the milk of lactating rats. Adverse behavioural effects were seen in offspring in a peri-post natal toxicity study in rats. Excretion of duloxetine and/or metabolites into human milk has not been studied. The use of XERISTAR while breast-feeding is not recommended. |
| Adverse Reactions : | Tables 1 and 2 give the frequency of adverse reactions from placebo-controlled clinical trials in depression and diabetic neuropathic pain. The adverse reactions reported in these tables are those events that occurred in 1% or more of patients treated with duloxetine and were reported significantly more often in patients taking duloxetine than placebo, or where the event was considered clinically relevant. The most commonly reported adverse reactions in patients treated with depression with XERISTAR were nausea, dry mouth and constipation. However, the majority of common adverse reactions were mild to moderate, they usually started early in therapy, and most tended to subside even as therapy was continued. The most commonly observed adverse reactions in patients with diabetic neuropathic pain treated with XERISTAR were: nausea; somnolence; dizziness; constipation and fatigue. Table 1 Very Common Adverse Reactions ( = 10%) System Organ Class Adverse Reaction XERISTAR (N=1592) (%) Placebo (N=1000) (%) Psychiatric disorders Insomnia 10 6 Nervous system disorders Dizziness Somnolence 11 10 5 3 Gastrointestinal disorders Nausea Dry mouth Constipation 22 13 12 7 6 4 Table 2 Common Adverse Reactions ( = 1%, < 10%) System Organ Class Adverse Reaction XERISTAR (N=1592) (%) Placebo (N=1000) (%) Metabolism and nutrition disorders Decreased Appetite Anorexia 6 2 2 <1 Psychiatric disorders Decreased Libido Anorgasmia Middle insomnia 2 2 1 <1 0 <1 Nervous system disorders Tremor Sedation Hypersomnia 3 1 a 1 1 <1 a <1 Eye disorders Vision blurred 3 1 Vascular disorders Hot flush 2 1 Respiratory, thoracic and mediastinal disorders Yawning 1 0 Gastrointestinal disorders Diarrhoea Vomiting 8 5 6 3 Skin and subcutaneous tissue disorders Increased Sweat Night sweats 7 1 2 <1 Musculoskeletal and connective tissue disorders Muscle tightness 1 <1 Reproductive system and breast disorders Erectile dysfunction* Ejaculation disorder* 5 2 1 <1 General disorders and administration site conditions Fatigue Lethargy Feeling jittery 9 1 1 4 <1 <1 Investigations Weight decreased 2 1 * Adjusted for gender (N Males = Duloxetine 660, Placebo 375) a Values rounded from a frequency of 1.3% (duloxetine) and 0.6% (placebo) Discontinuation symptoms have been reported when stopping XERISTAR. Common symptoms, particularly on abrupt discontinuation, include dizziness, nausea, insomnia, headache and anxiety (See Adult Dosage and Special Precautions). Duloxetine treatment in clinical trials was associated with numerically significant, but not clinically related increases in ALT, AST, alkaline phosphatase, and creatinine phosphokinase-CPK; transient, abnormal values of these enzymes were infrequently observed in duloxetine-treated patients, compared with placebo-treated patients. Duloxetine is known to affect urethral resistance. In placebo-controlled trials, urinary hesitation was reported rarely (< 1 %) in male patients. If symptoms of urinary hesitation develop during treatment with duloxetine, consideration should be given that they might be drug-related. In clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine-treated patients compared to placebo at 12 weeks and routine care at 52 weeks. The increase was similar at both time points and was not considered clinically relevant. Relative to placebo or routine care, mean HbA1c values were stable, there was no mean weight gain, mean lipid concentrations (cholesterol, LDL, HDL, triglycerides) were stable, and there were no differences in incidence of serious and non-serious diabetes-related adverse reactions. Electrocardiograms were obtained from 1139 duloxetine treated patients and 777 placebo-treated patients in 8-week clinical trials in major depressive disorder, and from 528 duloxetine-treated and 205 placebo-treated patients with diabetic neuropathic pain in clinical trials lasting up to 13-weeks. The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients. Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (See Special Precautions). |
| Manufacturer : | Boehringer Ingelheim |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org